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Abstract
Background: The mouse is one of the most widely used animal models to study neuromuscular diseases and test
new therapeutic strategies. However, findings from successful pre-clinical studies using mouse models frequently
fail to translate to humans due to various factors. Differences in muscle function between the two species could be
crucial but often have been overlooked. The purpose of this study was to evaluate and compare muscle excursions
in walking between mice and humans.
Methods: Recently published musculoskeletal models of the mouse hindlimb and human lower limb were used to
simulate muscle-tendon dynamics during mouse and human walking, a key daily activity. Muscle fiber length changes
(fiber excursions) of 25 muscle homologs in the two species were calculated from these simulations and then compared.
To understand potential causes of differences in fiber excursions in walking, joint excursions and muscle moment arms
were also compared across one gait cycle.
Results: Most muscles (19 out of 25 muscles) of the mouse hindlimb had much smaller fiber excursions as compared to
human lower limb muscles during walking. For these muscles, fiber excursions in mice were only 48 ± 19% of those in
humans. The differences in fiber excursion between the two species were primarily due to the reduced joint excursions
and smaller muscle moment arms in mice as compared to humans.
Conclusions: Since progressive neuromuscular diseases, such as Duchenne muscular dystrophy, are known to be accelerated
by damage accumulated from active muscle lengthening, these results suggest that biomechanical differences in muscle
function during walking between mice and humans may impede the translations of knowledge gained from mouse models
to humans. This knowledge would add a fresh perspective on how pre-clinical studies on mice might be better designed to
improve translation to human clinical trials.
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Background
The mouse is one of the most widely used animal models
to study neuromuscular diseases and test new treatments
[1]. Numerous mouse models of a wide variety of human
neuromuscular diseases have been developed, leading to
valuable insights about the underlying pathophysiology of
diseases and the identification of new potential therapeutic
strategies [2–5]. Although mouse models play a crucial
role for developing new therapies, treatments that succeed
in pre-clinical studies using mouse models often fail in
human trials [6–8]. Understanding the obstacles that limit
the translation of therapies from mouse to human will
accelerate future discoveries of new therapies, minimize
attrition of investigational drugs, and lower the associated
costs of financial, material, and human resources.
The difficulties in the translation from mouse pre-
clinical trials to successful human trials may arise from
two major sources [7]. First, flaws and inconsistencies in
experimental design, such as insufficient sample size,
improper randomization and blinding, and inappropriate
selection of readout parameters (among others), may
hinder this translation [9, 10]. In an attempt to address
these issues, guidelines for standardizing methodologic-
ally rigorous pre-clinical experimental studies on mouse
models have been established [11–13]. Second, anatom-
ical and physiological differences between mouse models
and their human counterparts may prevent the models
from accurately reflecting disease progression in humans.
For example, there are notable differences in ontogeny,
immunology, and pathology between mice and humans, as
well as considerable differences in the biomechanics of
musculoskeletal systems [1, 14, 15]. Although substantial
effort has been devoted to understanding the differences in
growth and pathophysiology between mice and humans,
the implications of the biomechanical differences between
two species often have been overlooked.
The biomechanical differences between mice and
humans could lead to the different phenotype appearing
in mouse models of neuromuscular diseases and the di-
minished utility of pre-clinical studies for predicting the
efficacy of new therapeutic treatments in humans. For
example, in the widely used mouse model (mdx mice) of
Duchenne muscular dystrophy (DMD), a genetic, pro-
gressive degenerative disorder of muscles affecting 1 in
3500 male births [16], the limb muscles in the mdx mice
have a much milder phenotype than those in humans
[17]. Differences in muscle function during daily loco-
motion, such as walking and running, between mice and
humans may contribute to this milder phenotype in
mice. For example, if mouse muscles stretch less during
movement than human muscles, the extent of stretch-
induced damage to dystrophic muscles would also be di-
minished [18–20]. However, whether the relative muscle
excursions of mice during daily locomotion are smaller
than those of humans remains unknown. In addition,
current standard protocols recommended by the TREAT-
NMD Neuromuscular Network [21] and many pre-
clinical studies [22–25] that aimed to test the efficacy of
new treatments in mouse models exercise mdx mice at
12 m/min (0.2 m/s). Although the forced walking exercise
at this speed tends to exacerbate muscle damage in mdx
mice [23, 24], the treatment efficacy demonstrated from
these pre-clinical studies has not translated well to
humans [26–31]. It is unclear whether the muscle fiber
excursions in mice during this type of exercise are com-
parable to those humans may experience. So far, although
sarcomere lengths of mouse muscle fibers at fixed joint
postures have been measured in vivo [32, 33], experimen-
tal studies alone have not been able to shed light on
muscle fiber excursions in mouse limb muscles during
daily locomotion. One underlying challenge is that due to
their small body size, it remains almost impossible to
experimentally measure dynamic in vivo muscle fiber ex-
cursions in mice even with the state-of-the-art techniques.
Musculoskeletal modeling and simulation provide a use-
ful non-invasive means to examine muscle function, such
as how muscle fibers change length during locomotion. In
musculoskeletal models, joint kinematics, muscle lines of
action from origin to insertion, and muscle architecture
parameters (such as physiological cross-sectional area,
optimal fiber length, and pennation angle) are estimated
based on extensive experimental measurements [34]. Each
individual muscle is modeled with one or multiple
muscle-tendon units from origin to insertion, and its
dynamic contractile capability is represented using Hill-
type muscle models [35]. The three-dimensional (3D)
musculoskeletal model of human lower limb developed by
Delp et al. [34] has been widely used to study human loco-
motion and has evolved through the years to incorporate
more accurate anatomic data from large-scale cadaver and
imaging studies [36, 37]. Simulation studies using this
model have evaluated the muscle fiber excursions in
human walking and running at various speeds [38, 39].
Recently, a 3D musculoskeletal model of a mouse’s
hindlimb [40] has been developed based on detailed ana-
tomical measurements from microCT scanning, digital
segmentation, and microdissection [41]. This model pro-
vides opportunities for simulation studies to examine the
functions of mouse hindlimb muscles during locomotion,
including the muscle fiber excursions, and to make com-
parisons with humans or other species.
The purpose of this study was to evaluate the muscle
fiber excursions of mouse hindlimb muscles in walking
and compare them to the excursions human lower limb
muscles may experience in walking. Mice are non-
cursorial quadrupeds [42] and therefore employ more
flexed hip and knee postures during locomotion [43] rela-
tive to the more cursorial (i.e., straight-limbed/upright)
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humans [44]. We therefore hypothesize that the fiber
excursions of mouse hindlimb muscles in walking are
smaller than those of human lower limb muscles. To test
this hypothesis, we used musculoskeletal models of the
mouse hindlimb [40] and human lower limb [37] to run
dynamic simulations of mice and humans walking at
their most frequently used speeds in locomotion and
to estimate fiber excursions of 25 muscle homologs in
these two species. These results will shed new light on
the potential implications of the biomechanical differ-
ences between mice and humans and could thereby
lead to a fresh perspective on how pre-clinical studies
on mice might be better designed to improve transla-
tion to human clinical trials. All the data and files
used to create the simulations are freely available at
https://simtk.org/projects/mice.
Methods
Musculoskeletal models
Two state-of-the-art 3D musculoskeletal models of
mouse hindlimb and human lower limb were used in
this study to develop forward dynamic simulations of
muscle-tendon dynamics during walking and estimate
muscle fiber excursions (Fig. 1). The musculoskeletal
model of a mouse hindlimb (https://simtk.org/projects/
mousehindlimb) [40] includes 7 degrees of freedom to
describe flexion/extension, adduction/abduction, and ex-
ternal/internal rotation of the hip joint; flexion/extension
of the knee joint; and dorsiflexion/plantarflexion, ever-
sion/inversion, and adduction/abduction of the ankle
joint. A total of 44 muscle-tendon units were used to
represent the 39 muscles of the mouse hindlimb and pelvis.
Similarly, the musculoskeletal model of the human lower
limbs (https://simtk.org/projects/full_body/) [37] includes 7
degrees of freedom for each leg to describe flexion/exten-
sion, adduction/abduction, and external/internal rotation of
the hip joint; flexion/extension of the knee joint; dorsiflex-
ion/plantarflexion and eversion/inversion of the ankle joint;
and flexion/extension of the metatarsophalangeal joint. A
total of 40 muscle-tendon units per leg were used to repre-
sent the 31 muscles of the human lower limb.
In both musculoskeletal models, each muscle was
approximated with one or more muscle-tendon units,
depending on the size of attachment areas. Each muscle-
tendon unit was represented as a massless series of line
segments defining the path of a muscle from its origin
to insertion [45]. A Hill-type muscle model [35] was
used to characterize the contraction dynamics and
force-generating capacity of each muscle-tendon unit.
This muscle model used an active contractile element in
parallel with a passive elastic element together to repre-
sent the muscle fiber and its active and passive force-
generating capacity. The tendon of each muscle-tendon
unit was represented using a non-linear, passive elastic
element and was in series with the muscle fiber which
had a pennation angle (α) (Fig. 2a). The mechanical
properties of muscle fiber and tendon were defined
using a set of generic fiber force-length, fiber force-
velocity, and tendon force-strain curves (Fig. 2b–d).
These curves were then scaled to characterize the
unique architectural and mechanical properties of each
muscle-tendon unit using five parameters (muscle maximum
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Fig. 1 Musculoskeletal models (right side; lateral view) of the mouse hindlimb and human lower limb during one gait cycle. Each muscle was
represented by one or multiple line-segment muscle-tendon units. The mechanical properties of each muscle-tendon unit were characterized by a
Hill-type muscle model [35], which used separate elements to represent tendon and muscle fiber (Fig. 2)
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isometric force FMo , optimal fiber length L
M
o , maximum fiber
shortening velocity VMmax, pennation angle at optimal fiber
length αo, and tendon slack length LTs ). These parameters
were derived from architectural data of each muscle gathered
experimentally from mice and human cadavers via dissections
and imaging techniques [37, 40, 41, 46], so the differences in
muscle architecture in various muscles in mice and humans
can be taken into account. In this model, activation (a) ranges
from 0 to 1, representing passive to fully activated muscles,
respectively. For muscle-tendon units in which the ratio of the
optimal fiber length to the tendon slack length (LMo =L
T
s ) was
larger than 2, tendons were assumed to be rigid considering
the computational expenses and the physiological structure of
muscles. This assumption only affected 10 muscles in mice
and 3 in humans out of 25 muscles that were compared
(Additional file 1: figure S1). These muscles were all upper leg
(thigh) muscles that had no or very short external tendons
[41, 47]. Therefore, tendon strain in these muscles should be
negligible, and assuming a rigid tendon for these muscles
allowed for significantly decreased simulation times [35] while
barely affecting estimates of muscle fiber excursion
(Additional file 1: figure S2). None of the lower leg
(shank) muscles with measurable external tendons
were affected. (see Additional file 1 for more explan-
ation and which specific muscles were affected by the
rigid tendon assumption.)
Simulation of fiber length changes during walking
Simulations were produced by inputting joint kinematics
previously published from two studies: 16 wild-type mice
walking on a treadmill at the speed of 0.2 m/s [43] and 5
healthy human subjects walking on a treadmill at
1.25 m/s [39]. Because speed affects fiber excursions
during locomotion [39], these two speeds were specific-
ally chosen because they are comparable in the context
of daily locomotion of two species. Previous studies have
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Fig. 2 The contraction dynamics and force-generating capacity of each muscle-tendon unit was represented by a Hill-type muscle model [35]. (a)
The total muscle-tendon length (LMT) was a function of the geometric pose of the musculoskeletal models of mouse hindlimb and human lower
limb. The muscle model computes muscle fiber length (LM), muscle pennation angle (α), tendon length (LT), muscle fiber force (FM), and tendon
force (FT) based on LMT, muscle activation (a), and the force equilibrium constraints between FM and FT. (b) Tendon was modeled as a non-linear,
passive series elastic element, whose mechanical property was defined by the tendon force-strain curve. In this curve, it was assumed that tendon
strain (εT) is 4.9% when muscle fiber developed maximum isometric force (FMo ). Tendon strain was calculated from the muscle-specific tendon slack
length (LTs ). (c) Muscle fiber was modeled as an active contractile element (CE) in parallel with a passive elastic element (PE). The active force-length
curve was scaled by muscle-specific optimal fiber length (LMo ) and then used to compute active isometric fiber force based on L
M and activation (a).
The passive force-length curve was also scaled by LMo and then used to compute passive fiber force based on L
M. (d) The active isometric fiber force
was scaled based on fiber velocity (VM) normalized by maximum shortening velocity (VMmax) of the muscle. Total muscle force was calculated as the
sum of active and passive fiber force
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shown that the average spontaneous free walking speeds
of mice and humans are about 0.2 [48, 49] and 1.25 m/s
[44], respectively.
Forward dynamic simulations of muscle-tendon dynam-
ics during walking were developed using an open-source
musculoskeletal simulation platform, OpenSim version 3.2
(https://simtk.org/projects/opensim) [50]. Experimentally
measured joint kinematics of one gait cycle of each indi-
vidual mouse and human was prescribed in the simula-
tions. Because the mouse kinematic data from Akay et al.
[43] were only available in the sagittal plane, including
flexion/extension at the hip, knee, and ankle joints, kine-
matic data from humans were simplified to only include
these degrees of freedom with all other degrees of freedom
locked at default positions. To consider the influences of
muscle activation on the possible ranges of fiber excur-
sions, simulations were created with two activation cases
(Fig. 3). In the first set of simulations, the activation levels
for all the muscles were set to be a constant value of 1
(maximal activation). In the second set of simulations, the
activation levels for all the muscles were set to be a
constant value of 0.05 (minimum activation). The mini-
mum activation was set at 0.05 to avoid numerical singu-
larity in the muscle model when activation approaches 0
[35]. For both sets of simulations, the identical joint angle
trajectories were prescribed based on the experimental
data. Forward dynamic simulations were then run to
calculate muscle fiber length (LM) based on muscle-
tendon length (LMT), prescribed muscle activation (a), and
the force equilibrium constraints between fiber force (FM)
and tendon force (FT) that satisfied the prescribed motion
[51]. Outputs of muscle fiber length were then analyzed to
obtain fiber excursion (see Data analyses). All the simula-
tions were developed using the generic models of the
mouse hindlimb and human lower limbs and the specific
joint kinematics that were measured from each individual
mouse or human subject.
Data analyses
Fiber length changes of each muscle-tendon unit during
one gait cycle were estimated for the maximum and
minimum activation cases separately and were then normal-
ized to each muscle’s optimal fiber length. The muscle fiber
excursions in walking were defined as the difference between
the maximum fiber length when activation was 0.05 and the
minimum fiber length when activation was 1 (Fig. 3). For a
muscle approximated by multiple muscle-tendon units, fiber
excursions of those muscle-tendon units were averaged to
represent the mean fiber excursion of that whole muscle.
Fiber excursions of 25 muscles that have homologs in the
two species and are available both in musculoskeletal models
of mice hindlimb and human lower limb were compared
using a t-test with p values corrected by the Holm–Bonfer-
roni method. The p value for significance was set at 0.05.
To understand potential causes of differences in fiber
excursion in walking, we also compared the joint excur-
sions and muscle moment arms between all mice and
human subjects across one gait cycle. These analyses
were performed because changes in length of a muscle-
tendon unit are determined by: (i) the excursion of the
joint it spans and (ii) its moment arm with regard to
that joint [52]. Ranges of excursions for the hip, knee,
and ankle joints were computed as the differences
between the largest and the smallest joint angles in one
gait cycle from the prescribed joint kinematics in the
simulations. In addition, muscle flexion/extension mo-
ment arms at the hip, knee, and ankle in one gait cycle
were calculated, averaged across one gait cycle, and then
normalized by each muscle’s optimal fiber length. Simi-
lar t-tests with p value set at 0.05 were used to compare
excursions of each joint and normalized muscle moment
arms of each muscle (also corrected by Holm–Bonfer-
roni method) between mice and human subjects.
To examine the potential impact of muscle fiber
excursions in walking to the differential involvement in
limb muscles in neuromuscular diseases, such as DMD,
linear regression analyses were conducted to examine
whether correlation exists between fiber excursions dur-
ing gait and the fat fraction in patients with DMD, which
is a metric of the extent of muscle degeneration. In the
linear regression analyses, the fiber excursions were the
average of excursions of individual muscle across five
healthy human subjects (red bars in Fig. 4), and the fat
fractions were acquired from a study by Wokke et al.
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Fig. 3 Simulated fiber length changes of the vastus lateralis muscle
in dynamic models of mouse and human during one gait cycle.
Fiber excursion in walking was defined as the difference between
the maximum fiber length when activation (Act) was 0.05 and the
minimum fiber length when activation was 1
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[53], which quantified the fat fractions of lower limb
muscles in 16 patients with DMD using quantitative
magnetic resonance imaging (Fig. 2 in [53]). Separate
linear regression analyses were conducted for upper leg
and lower leg muscles (Fig. 4), respectively, because
proximal upper leg muscles are generally more affected
than the distal lower leg muscles in DMD [53, 54]. Four
upper leg muscles (gluteus maximus, adductor brevis,
psoas, and iliacus) of which fat fractions were not
reported in [53] were not included in the analyses. Fiber
excursions of peroneus longus and peroneus brevis were
averaged in the analyses since the fat fraction was mea-
sured from the whole peroneus muscle in [53]. The level
of significance was set at p < 0.05.
Sensitivity analyses
Because of the intrinsic variability in physiological pa-
rameters of the muscle model, sensitivity analyses were
conducted to evaluate the sensitivity of fiber excursions
estimated from our simulations to two muscle-specific
parameters: optimal fiber length LMo and tendon slack
length LTs , as well as one parameter that defines normal-
ized generic tendon force-strain curve: the tendon strain
εTo when the normalized tendon force is one. Specifically,
LMo and L
T
s of each muscle-tendon unit were varied by
its ± 1 standard deviation reported in [37, 41]. εTo is a
parameter that defines the shape of the default generic
force-strain curve of tendon, essentially the stiffness of
the tendon. It has a default nominal value of 4.9% in the
muscle model [35] and a plausible range of 2–9% [45].
Therefore, sensitivity analyses of εTo were conducted by
setting its values at 2 and 9%, representing the stiffest
and most compliant scenarios, respectively.
Sensitivity analyses were conducted separately for the
mouse hindlimb model and human lower limb model.
For each species, the averaged joint kinematics in one
gait cycle across either all mice or all human subjects
were prescribed. Dynamic simulations were first run
with all three parameters at their default values to produce
the nominal fiber excursions of each of the 25 muscles
compared. Next, dynamic simulations were run with vary-
ing one parameter (LMo or L
T
s by ± 1 standard deviation, or
εTo at 2 or 9%) while holding other two at their default
values. The differences between the nominal fiber excur-
sions and those excursions obtained with one of the three
parameters varied were calculated and normalized by the
optimal fiber length of each muscle. The sensitivity of
fiber excursions to a given parameter was reported as the
averaged differences across 25 muscles.
Results
Most muscles of the mouse hindlimb had smaller
fiber excursions during walking as compared to those of
human lower limbs (Fig. 4). Out of the 25 muscles
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compared, 19 muscles had significantly smaller fiber excur-
sions in mice as compared to humans. The fiber excursions
of these muscles on average were ð0:25 0:15Þ  LMo
(mean ± standard deviation) smaller in mice than in
humans. That is, the fiber excursions of these muscles in
mice were only 48 ± 19% of those in humans. By contrast,
only three muscles (gracilis, soleus, and peroneus brevis)
had significantly larger fiber excursions in mice than in
humans, and three muscles (adductor magnus, semitendi-
nosus, and flexor digitorum longus) had comparable fiber
excursions in the two species.
The joint excursions at the hip, knee, and ankle dif-
fered between mice and humans during walking
(Fig. 5a). The differences were most pronounced at
the knee and ankle joints. The knee joint excursion
was 40.3° smaller in mice than in humans (Fig. 5b)
because the knee joint of mice was kept at much
more flexed joint angles (minimum knee flexion angle
90.5°) than that of humans (maximum knee flexion
angle 68.3°). By contrast, the ankle joint excursion
was 43.3° larger in mice than in humans, largely be-
cause mice dorsiflexed their ankles more than human
subjects did, especially at the beginning of the stance
phase and the end of the swing phase (Figs. 1 and
5b). While there was a statistical difference in the hip
joint excursion between mice and humans, the differ-
ence was only 12.4° (Fig. 5a).
Almost all mouse hindlimb muscles had significantly
smaller normalized average moment arms than human
lower limb muscles during walking (Fig. 6). Seven out
of 11 muscles crossing the hip joint, 8 out of 10 mus-
cles crossing the knee joint, and all 10 muscles crossing
the ankle joint had significantly smaller normalized
flexion/extension moment arms in mice than in humans.
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For these muscles with smaller moment arms, the normal-
ized moment arms in the mouse hindlimb were on aver-
age ð0:19 0:10Þ  LMo , ð0:26 0:09Þ  LMo and
ð0:30 0:17Þ  LMo smaller than in the human lower limb
for the hip, knee, and ankle joints, respectively. Only a few
muscles had larger normalized moment arms during walk-
ing in mice than in humans. Adductor magnus and psoas
had larger normalized moment arms at the hip joint. Gra-
cilis and semitendinosus (both biarticular muscles) had
larger normalized moment arms at the hip and the knee
joints.
Muscle fiber excursions quantified from our walking
simulations were significantly correlated with the fat
fractions in patients with DMD. In general, fat frac-
tions increased with fiber excursions in walking in
both upper and lower leg muscles (Fig. 7). The only
exceptions were the adductor magnus in the upper
leg and the peroneus in the lower leg, both of which
had high fat fractions despite experiencing low fiber
excursions during walking. Excluding these two mus-
cles, linear regression analyses showed significant cor-
relations between fiber excursions and fat fractions in
upper leg (r2 = 0.55, p = 0.017) and lower leg mus-
cles (r2 = 0.76, p = 0.005).
The simulation-based estimates of muscle fiber ex-
cursions during walking were not sensitive to changes
of parameters in either model (Fig. 8). Varying optimal
fiber length LMo by ± 1 standard deviation resulted in
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the largest variation of the muscle fiber excursions.
However, these variations were on average only less
than 0:07  LMo in both the mouse hindlimb model and
human lower limb model. Similarly, varying LTs and ε
T
o
only led to variations of less than 0:05  LMo in the
muscle fiber excursions.
Discussion
The purpose of this study was to compare the muscle
fiber excursions during walking of mouse hindlimb mus-
cles with their homologs in human lower limbs. This
was accomplished by running forward dynamic simula-
tions with prescribed joint kinematics obtained from
existing studies [39, 43]. Recently published musculo-
skeletal models of the mouse hindlimb [40] and human
lower limb [37] were used to run simulations. Our simu-
lation results suggested that most muscles (19 out of 25
muscles) in the mouse hindlimb had length changes
during walking that were only about 48% of the length
changes in human lower limb muscles. We found that
the smaller muscle fiber excursions in mice were primar-
ily due to differences in the walking kinematics (e.g.,
more crouched limb posture and reduced ranges of joint
motion in mice) and muscle moment arms (relatively
smaller overall in mice). We also found that the amount of
fiber excursion significantly correlated to the differential
muscle involvement in limb muscles in patients with DMD.
These results revealed important biomechanical differences
in muscle fiber function during walking, a key daily activity,
and have important implications for the utility of mouse
models to study neuromuscular diseases and test new
treatments.
Causes of smaller fiber excursions in mice as compared to
humans
Differences in gait kinematics, muscle geometry, and
muscle architecture all contributed to the finding that
muscle fiber excursions were generally smaller in mice
than in humans (Fig. 4). Considering the much smaller
body mass of mice vs. humans, the muscles must have
adapted accordingly to meet the requirements of gener-
ating movement and supporting against gravity in these
two species. Among these adaptations, muscle moment
arm allometrically increases with body mass [55, 56],
whereas relative optimal fiber length (optimal fiber
length/muscle belly length) allometrically decreases with
body mass [57], a pattern that can be observed in com-
paring mice with humans (Fig. 9). The combined effect
was that mice had smaller normalized moment arms
(moment arm/optimal fiber length) in most muscles (11
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out of 15 muscles) acting across the hip and knee and all
muscles acting across the ankle (Fig. 6). These geomet-
rical and architectural adaptations in mice as well as
significantly smaller ranges of joint excursion at the hip
and knee (Fig. 5a) played crucial roles in the smaller
fiber excursions in mice as compared with humans.
Conversely, to support a larger body mass, humans have
larger muscle moment arms, shorter relative optimal
fiber lengths, and an upright bipedal gait, as compared
to crouched, quadrupedal gait of mice [55, 56]. Although
these differences provide humans with sufficient muscle
strength for movement and gravitational support while
preventing mechanical overload to the musculoskeletal
system, they inevitably lead to greater muscle fiber
excursions in humans than in mice, which may be dev-
astating under certain neuromuscular diseases, such as
DMD. In land mammals, given that normalized moment
arms increase [55–57] but limb joint excursions decrease
[58, 59] with increasing body mass, whether greater body
mass would allometrically lead to larger limb muscle fiber
excursions and therefore possibly more damaging effects
in neuromuscular diseases [60] needs to be determined by
more comprehensive comparative studies.
Potential impact of fiber excursions on differential
disease involvement in limb muscles
The variation in fiber excursions may contribute to
the differential involvement across muscles in neuro-
muscular diseases. It has been well documented that
in certain neuromuscular diseases, especially muscular
dystrophies, muscles can be affected differently by
one disease [54]. In DMD, recent imaging studies
have provided a comprehensive picture of the select-
ive muscle degeneration across lower limb muscles
[53, 61]. Integrating the results from an imaging study
[53], our analyses showed strong correlations between
fiber excursions and fat fractions in lower limb
muscle in patients with DMD (Fig. 7), which sug-
gested a potential contribution from fiber excursion
to the differential muscle involvement in DMD. In
terms of mdx mice, to authors’ best knowledge, only
a few studies have evaluated muscle degeneration
across several hindlimb muscles [22, 62, 63]. It has
been reported that soleus exhibits more profound de-
generation as compared to extensor digitorum longus
(EDL) and tibialis anterior (TA) at the beginning of
ambulation (~ 3 to 4 weeks old) [62, 63]. Considering
that EDL and TA of mice are more prone to damage
than soleus due to their mostly fast fiber composition
[20, 64], it is likely that the much greater muscle ex-
cursion in soleus than in EDL and TA (Fig. 4) plays
an important role to the observed selective degener-
ation across these muscles. These potential links be-
tween fiber excursion and differential disease
involvements within mice or humans suggested pos-
sible roles of fiber excursion on the differences in
phenotypes between these two species.
Influence of diminished fiber excursion on different
phenotypes between mice and humans
The biomechanical differences in muscles during walk-
ing may contribute to different phenotypes between
mouse models of neuromuscular diseases and their hu-
man counterparts, thereby impeding the translation of
successful pre-clinical trials using mouse models to
human trials. At comparable speed, a majority of mouse
hindlimb muscles have smaller fiber excursions than
those of human lower limbs (Fig. 4). These results sug-
gested a smaller magnitude of muscle fiber lengthening
(and shortening) in every gait cycle in mice compared
with humans, meaning that muscles in mice hindlimbs
and in human lower limbs may work under quite differ-
ent repeated biomechanical loads in walking. These rela-
tively smaller biomechanical loads in walking mice may
trigger different cascades of pathological and inflammatory
responses that result in differing phenotypes appearing in
mouse models of neuromuscular diseases. Specifically for
DMD, although several factors, such as differences in
stature, growth, and inflammatory responses, may all con-
tribute to the alleviated phenotype of mdx mice [1, 60], the
biomechanical difference in walking revealed in this study
may also play an important role. Since larger magnitudes of
muscle lengthening, no matter passive or active, have been
shown to cause more damage to muscles, especially dys-
trophic muscles [19, 65, 66], it is likely that the smaller
magnitudes of muscle lengthening may alleviate muscle
damage and therefore contribute to milder phenotypes in
mdx mice hindlimb muscles compared with patients with
DMD. Therefore, although mdx mice have been recom-
mended as the model of choice for proof-of-concept and
pre-clinical studies [67], cautious interpretation of the
results is required, given the biomechanical differences dur-
ing locomotion between mice and humans revealed in the
current study.
Implications for exercise protocols using mouse models
The biomechanical differences in muscles during walk-
ing may influence to what extent the current exercise
protocols performed in studies using mouse models of
neuromuscular disease are relevant to human patients.
Exercise protocols are often used to evaluate the impact
of certain types and intensities of exercises on the
disease state of mouse models [68–71] and to exacerbate
disease states to more rigorously evaluate potential
therapeutic interventions in pre-clinical trials with
mouse models [22–25]. However, it has been controver-
sial whether the findings from these exercise studies
may be extrapolated to humans due to possible
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biomechanical differences between mice and humans
[70]. In DMD, our results showed that mice walking at
the recommended exercising speed had smaller fiber ex-
cursions (Fig. 4) and therefore smaller magnitudes of
muscle fiber lengthening than humans walking at com-
parable, natural walking speed. Thus, the treatments
showing efficacy in these exercised mice may not be
similarly effective in humans [26–31]. It is plausible that
exercising mice at higher speeds may impose larger mag-
nitudes of muscle fiber lengthening that is more relevant
to humans [39, 49]. In addition, although alternative
animal models for DMD with larger body sizes, such as
golden retriever muscular dystrophy dogs [15, 72], have
been considered as better models of DMD, similar stud-
ies may be needed to determine whether muscle fiber
excursions in these animal models may more closely
approximate those of humans in walking.
There have been studies using downhill exercise to
exacerbate muscle damage in mice [73–75]. Although
we have not been aware of any detailed studies on kine-
matics of mice walking downhill, animals with small
body mass (e.g., mice) tend to use shorter strides in
downhill walking than in level walking [76], which may
lead to slightly smaller fiber excursions. The overall
greater muscle damage in mice via downhill exercises
was likely because of increased muscle activation during
lengthening in order to dissipate energy and maintain
locomotor velocity [76–78].
Comparison with sarcomere length measured in
experimental studies
Recent advances in imaging techniques have made pos-
sible to visualize and measure sarcomere lengths in vivo
at fixed joint configurations [32, 33]. Measurements
from these studies were often compared with those pre-
dicted by lumped parameter Hill-type muscle model as
used in this study, which essentially assumed the whole
muscle as a scaled-up sarcomere. In the human vastus
lateralis and soleus, ranges of sarcomere length changes
predicted by a lumped parameter model were larger than
experimental measurements at two joint angles [79, 80].
Similarly, we found that the changes of sarcomere
lengths of the lateral gastrocnemius and tibialis anterior
muscles predicted in our simulations were relatively lar-
ger than those experimentally estimated in vivo in mice
[32, 33]. The simplifications that all the fibers may be
modeled by one sarcomere and have the same moment
arm likely led to the overestimation of the changes in
sarcomere lengths in Hill-type muscle models [81].
Finite-element models incorporating the complex details
of muscle architecture [18] and/or experimental mea-
surements of regionally heterogeneous strains in muscles
[82–84] may be needed to overcome these limitations,
which, however, are not practically feasible for large-
scale analyses systematically across many muscles, such
as this study’s analyses. Nevertheless, because the Hill-
type muscle model with muscle- and species-specific
architectural parameters was used to simulate fiber
excursions in both mice and humans, which captures
the general architectural characteristics of each individ-
ual muscle in both species (e.g., more parallel-fibered
proximally and pennate distally in both species), our
conclusions from comparisons of fiber excursions should
not be appreciably altered.
Sensitivity of model predictions to plausible parameter
variations
Our simulated muscle fiber excursions were robust with
respect to changes in model parameters within the range of
physiologically plausible variations. The sensitivity analyses
indicated that the predicted fiber excursion was most sensitive
to optimal fiber length LMo (Fig. 8). However, the variation in
LMo only resulted in changes of fiber excursions (<0:07  LMo )
that were much less than average differences of muscles be-
tween mice and humans ( ð0:25 0:15Þ  LMo ). For other
parameters in the Hill-type muscle model (FMo , V
M
max, and αo),
variations in FMo do not influence the relative length
changes in muscle fiber and tendon since mechanical
properties of muscle fiber and tendon are both normalized
to FMo [39]. Most muscles in the mouse hindlimb and hu-
man lower limb have αo smaller than 20° and standard de-
viations smaller than 5°, which should barely affect
contraction dynamics of muscle-tendon units [37, 41, 45].
Although simulations of movements involving rapid
muscle contractions, such as sprinting and jumping for
maximum height, may be sensitive to VMmax [85, 86], simula-
tions of walking generally require only muscle contractions
at slow speed and therefore should not be sensitive to the
variation in VMmax [38].
Influences from muscle activations on fiber excursion
The influences of muscle activations on the simulated
muscle fiber excursions were moderate and dependent
on the ratio of tendon slack length to optimal fiber
length. It is essentially impossible to acquire exact acti-
vation profiles of all 25 muscles in mouse hindlimb due
to limitations with electromyography technology for
measuring muscle activity in very small muscles. Therefore,
fiber excursions were estimated from two sets of simulations
with muscle activations at 0.05 or 1, which encompassed
fiber length changes resulted from any possible muscle acti-
vation profiles during walking. On average, fully activating
muscle-tendon units in our simulations moderately
increased possible fiber excursions by ð0:05 0:06Þ  LMo
and ð0:09 0:07Þ  LMo in the mouse hindlimb and human
lower limb, respectively. Most muscles crossing the hip and
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knee joints have relatively short, stiff tendons (LMo =L
T
s > 0:5)
that barely get stretched when these muscles are activated.
Therefore, these muscles were largely not subject to influ-
ences from muscle activations [38]. In contrast, most mus-
cles crossing the ankle joint have relatively long, compliant
tendons (LMo =L
T
s < 0:5), in which when fully activated, ten-
don stretches could somewhat increase fiber excursions.
Nevertheless, the influences from activation may only add
limited uncertainties to the comparisons of a few out of 25
muscles (e.g., flexor digitorum longus, tibialis posterior, pero-
neus longus, and peroneus brevis) rather than substantially
altering our overall results.
Conclusions
The physiological and anatomical musculoskeletal struc-
tures of mice and humans are biomechanically quite dif-
ferent because of their very different body sizes and
evolutionary histories, leading to disparate locomotor
mechanisms such as limb posture and musculoskeletal
stiffness [56]. To complicate the situation even more,
there are biomechanical differences in how they use their
musculoskeletal systems during daily locomotion as shown
in the current study, and perhaps during other daily living
tasks. Our simulation results demonstrated biomechanical
differences that could contribute to different disease states
between mouse models of neuromuscular diseases and
human patients. These differences may also impede the
translations of knowledge gained from mouse models to
humans. By understanding and accounting for these differ-
ences, experiments in mice may be better designed to gain
knowledge that could be translated to humans.
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